PSMA Inhibitor
- 1
- 2
-
PSMA-IN-2
0 ImagesCat. No.: HY-149298CAS No.: 2946600-14-0PSMA-IN-2 is an inhibitor of PSMA with a Ki value of 1.07 nM. PSMA-IN-2 displays favorable in vivo NIR imaging (λEM = 1088 nm, λex = 808 nm), and can be used for NIRII image-guided tumor resection surgery in PSMA-positive tumor-bearing mice.
-
PSMA-IN-3
0 ImagesCat. No.: HY-149869CAS No.: 2941187-68-2PSMA-IN-3 (compound 17) is a novel high-affinity PSMA inhibitor with an IC50 value of 13 nM. PSMA-IN-3 is suitable for developing an 18F-labeled radioligand for PET imaging of PSMA in prostate cancer.
-
DCFBC
0 ImagesCat. No.: HY-121659CAS No.: 564482-79-7DCFBC is a prostate-specific membrane antigen (PSMA) inhibitor that can be used for small animal positron emission tomography (PET) imaging. DCFBC labeled with F18 ([18F]DCFBC) can images in severe combined immunodeficient mice. [18F]DCFBC uptake is higher in PIP tumors, but almost absent in FLU tumors. [18F]DCFBC uptake is also high in the kidney and bladder, but the radioactivity washout time is shorter than that in PIP tumors. Indicating that [18F]DCFBC can specifically localize to PSMA+ expressing tumors and is applicable to the study of prostate cancer.
-
(R)-Zadavotide guraxetan
0 ImagesCat. No.: HY-P10951CAS No.: 2647371-60-4Synonyms: (R)-PSMA I&T; (R)-PNT-2002
-
Vidoflufolastat
0 ImagesCat. No.: HY-189131CAS No.: 1628717-55-4Synonyms: CTT-1057Vidoflufolastat (CTT-1057) is a PSMA inhibitor with an IC50 of 0.4 nM. Vidoflufolastat binds irreversibly to the active-site zinc ion through its phosphoramidate core, while its distal fluorobenzoyl ring interacts with the arene-binding site. Vidoflufolastat can be used in research on prostate cancer and Pseudomonas aeruginosa infection.
-
Capromab
0 ImagesCat. No.: HY-P992094CAS No.: 151763-64-3Capromab is an anti-human PSMA-targeting monoclonal antibody. Capromab binds specifically to the intracellular domain of PSMA, does not undergo internalization after binding, and targets necrotic cells with disrupted membranes. Capromab can be used for the research of prostate cancer.
- 1
- 2
